Six Requirements for Social Media Presence & Onboarding Instructions for ALL Team Members of LPBI Group
Curator: Aviva Lev-Ari, PhD, RN
Pre-Admission Phase
- Send an MS Word version of your CV
- Send 12 Research Categories from the Ontology of our Journal
- Schedule a One hour Interview with Dr. Lev-Ari on Zoom.
- Decision on Invitation to Join LPBI Group is made
- CV Uploaded to the Cloud in one category on OUR TEAM
- Receive the LINK to your CV and your Personal Page to report progress
- Please proof read. Send me corrections
Onboarding process start NOW. Granting you access to our platform: Author level
- I am sending you an INVITATION to join, NOW
- You accept the invitation
- You create a User Name and Password ONLY for this site
- Your create account and upload a Gravatar picture
- You post a one page post in one of the 12 Categories of research selected – you need to be on the DASHBOARD click on Add new post. [you create a MS Word file and you Copy and Paste, you have to add Article title AND
- Name of Author/Curator, Title as appears on CV, i.e., Indraneel Ghosh, PhD, Inventor Biologics, Lead on LPBI India Synthetic Biology Drug Discovery Team
- Select 5 categories for this post and
- Add 5 tags,
- Add reference as SOURCE,
- Search the Journal for:
-
Other related articles published in this Open Access Online Scientific Journal, include the following
-
List 5 Title, author, URL
Amandeep can help with All of the instructions, above
- As you click Publish – your picture will show on the Home Page
You follow these Six requirements, SEE below https://pharmaceuticalintelligence.com/2015/09/01/six-requirements-for-social-media-presence-all-team-members-of-lpbi/
You e-mail me that you are DONE to schedule the Zoom One-on-One
- This first Post, you need to convert Text to Audio into a Podcast by these instructions: https://pharmaceuticalintelligence.com/2021/07/14/standard-operating-procedures-for-text-to-audio-conversion-how-to-create-a-podcast-and-embed-it-on-a-post-or-on-a-page/
- You Open a DropBox Account by these Instructions: https://pharmaceuticalintelligence.com/2021/07/14/procedure-for-creating-a-dropbox-account/
Training on NLP and on Synthetic Biology Software will start in Mid-August 2021.
1st meeting with Dr. Nir and the Team assigned to Dr. Ghosh on Mission #2 will take place in mid September 2021
GOOD LUCK
NOW follow these SIX requirements:
- You Placed your LinkedIn Picture Gravatar on LPBI site on
so your picture will be AMONG the EAWs on the Home Page
- You Follow by e-mail Open Access Online Scientific Journal
http://pharmaceuticalintelligence.com
- You Liked our LPBI FaceBook.com Page
http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence
- You follow our LPBI on Twitter.com
- You JOINED LinkedIn THREE Groups Launched and managed by Aviva on LinkedIn
https://www.linkedin.com/groups/2987122
https://www.linkedin.com/groups/4357927
https://www.linkedin.com/groups/4346921
- You follow our LPBI Group’s Company Page on LinkedIn
6.1 IF YOU ARE A FINAL IMPROVEMENT TEAM (FIT) MEMBER you need to join
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.